Propanc Health Group Corporation is a biotech company focusing on developing new treatments for chronic diseases like cancer. Propanc recently announced early animal study results showing its proenzyme compounds were not associated with adverse effects and are ready for further research. The compounds have potential as effective long-term cancer therapies without the toxicity of current treatments, and could target solid tumors. However, more clinical trials are needed to confirm the preliminary findings.

1. (NU) - Biotech companies
are making a big splash in 2015,
offering potential investors a
compelling roster of options.
Among those to watch: Propanc
Health Group Corporation
(PPCH). Propanc is a develop-
mental-stage health care com-
pany that is currently focusing
its efforts in the field of new
treatments for chronic diseases,
particularly solid tumor cancers.
The company was established in
2007 and is headquartered in
Melbourne, Australia.
Propanc recently announced
early data from animal studies us-
ing its patented formulas.
Propanc’s in-development prote-
olytic proenzyme products (de-
scribed by the company as inac-
tive precursors of enzymes) were
not associated with any adverse
events in the early studies, and the
company is prepared to take the
next steps in research. According
to the company’s website, Propanc
“intends to undertake Phase I, II
and III clinical trials to assess the
safety and efficacy of our product
in specific patient populations.”
Propanc’s proenzyme prod-
ucts, known as PRP and PRP-
DCM, have the potential to be
game-changers for cancer care by
offering an effective option for
long-term therapy without the ex-
cessive toxicity associated with
many current cancer treatments.
The research is preliminary, and
the findings must be confirmed in
clinical trials. However the com-
pany’s stated development goals
focus on the targeting of solid tu-
mors, conditions for which most
currently available treatments are
limited to stabilizing the tumors or
extending patients’ lives for only
a few months. Solid tumor cancer
types include lung cancer, col-
orectal cancer, ovarian cancer,
pancreatic cancer and liver cancer.
As the company states, “In
each of these indications, there is
a large market opportunity to
capitalize on the limitations of
current therapies.”
Scientists don’t yet fully un-
derstand how proenzyme prod-
ucts can fight cancer, but early re-
search results suggest that they
may contribute to an inhibition of
growth factors that cause cancer.
In addition, Propanc is exploring
a method to shrink tumor masses
by targeting the tumor directly
with an injectable form of PRP.
Propanc also is working with
research collaborators to explore
how Propanc’s proenzyme prod-
ucts impact cancer cells. The goal
of this research is to provide an op-
portunity for new, patentable drug
development by the company.
For more information on
PPCH, visit www.propanc.com.
Anti-Cancer Compounds Show
Promise in Early Research
HEALTH
NewsUSA
Biotech Company Propanc
Offers Promising
Cancer Treatments
NewsUSA